SCHEMBL3306899

SCHEMBL3306899

Cc1cc(Nc2ccnc(Nc3ccc(S(=O)(=O)N4CCCC(O)(CN5CCCC5C)C4)cc3)n2)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 2/20 0.39
CDK4 P11802 1/20 0.39
CCNE1 P24864 1/20 0.39
IKBKB O14920 9/20 0.38
CHUK O15111 7/20 0.38
CYP19A1 P11511 1/20 0.38
MAPT P10636 2/20 0.38
TP53 P04637 1/20 0.38
JAK2 O60674 2/20 0.37
JAK3 P52333 2/20 0.37
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
AURKA O14965 1/20 0.34
MAP4K4 O95819 1/20 0.34
PIM1 P11309 1/20 0.34
MAPK8 P45983 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3295592 0.94 CDK2 (0.41) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3303273 0.92 IKBKB (0.41) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3304745 0.92 IKBKB (0.41) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3306444 0.92 IKBKB (0.41) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3299578 0.89 MAPT (0.42) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3300227 0.88 CDK4 (0.41) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3299288 0.87 CCNE1 (0.38) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3306623 0.86 JAK2 (0.42) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3301913 0.85 JAK2 (0.40) CDK2CDK4CCNE1IKBKBCHUK
SCHEMBL3300385 0.83 KMT2A (0.41) CDK2CDK4CCNE1IKBKBCHUK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE CDK2 8/4885CDK4 55/4885CCNE1 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.